This glycoprotein has been targeted using a variety of inhibitors and small molecules, most commonly labeled with 68Ga and 18F. During the last decade, PSMA-targeted positron emission tomography (PET) has become a substantial part of the imaging of prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.